The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes
出版年份 2019 全文链接
标题
The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes
作者
关键词
-
出版物
Journal of Clinical Medicine
Volume 8, Issue 11, Pages 1814
出版商
MDPI AG
发表日期
2019-11-02
DOI
10.3390/jcm8111814
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial
- (2019) David Fitchett et al. CIRCULATION
- How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial
- (2019) Agnes Bosch et al. Cardiovascular Diabetology
- Relationship Between Oxidative Stress, ER Stress, and Inflammation in Type 2 Diabetes: The Battle Continues
- (2019) Burgos-Morón et al. Journal of Clinical Medicine
- Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors
- (2018) Sarayut Lahnwong et al. Cardiovascular Diabetology
- Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress
- (2018) Mahmoud El-Daly et al. VASCULAR PHARMACOLOGY
- 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2019
- (2018) DIABETES CARE
- Sodium-glucose cotransporter inhibitors and oxidative stress: An update
- (2018) Habib Yaribeygi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2018) Thomas A Zelniker et al. LANCET
- Anti-inflammatory effects of empagliflozin in patients with type 2 diabetes and insulin resistance
- (2018) Sachiko Hattori Diabetology & Metabolic Syndrome
- Low testosterone levels are related to oxidative stress, mitochondrial dysfunction and altered subclinical atherosclerotic markers in type 2 diabetic male patients
- (2017) Susana Rovira-Llopis et al. FREE RADICAL BIOLOGY AND MEDICINE
- Inflammatory mechanisms linking obesity and metabolic disease
- (2017) Alan R. Saltiel et al. JOURNAL OF CLINICAL INVESTIGATION
- Novel Diabetes Drugs and the Cardiovascular Specialist
- (2017) Naveed Sattar et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
- (2017) Sebastian Steven et al. Redox Biology
- Executive Summary: Heart Disease and Stroke Statistics—2016 Update
- (2016) Dariush Mozaffarian et al. CIRCULATION
- Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes
- (2016) Samy Hadjadj et al. DIABETES CARE
- Sodium–glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis
- (2016) Harindra Rajasekeran et al. KIDNEY INTERNATIONAL
- Nephron Protection in Diabetic Kidney Disease
- (2016) Hans-Joachim Anders et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Insulin Resistance in PCOS Patients Enhances Oxidative Stress and Leukocyte Adhesion: Role of Myeloperoxidase
- (2016) Victor M. Victor et al. PLoS One
- Nuevos hipoglucemiantes orales y riesgo cardiovascular. Cruzando la frontera metabólica
- (2016) Belén Dalama et al. REVISTA ESPANOLA DE CARDIOLOGIA
- Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes
- (2016) Seok Joon Shin et al. PLoS One
- Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study
- (2015) Rimei Nishimura et al. Cardiovascular Diabetology
- Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Giulia Ferrannini et al. DIABETES CARE
- Blood Pressure Lowering in Type 2 Diabetes
- (2015) Connor A. Emdin et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
- (2015) Caroline Bonner et al. NATURE MEDICINE
- Regulation of metabolism by the innate immune system
- (2015) Denise E. Lackey et al. Nature Reviews Endocrinology
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial
- (2014) Hans-Ulrich Häring et al. DIABETES CARE
- A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes
- (2014) M. Monami et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
- (2014) Aurora Merovci et al. JOURNAL OF CLINICAL INVESTIGATION
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity
- (2014) Matthias Oelze et al. PLoS One
- Is Myeloperoxidase a Key Component in the ROS-Induced Vascular Damage Related to Nephropathy in Type 2 Diabetes?
- (2013) Susana Rovira-Llopis et al. ANTIOXIDANTS & REDOX SIGNALING
- Human Leukocyte/Endothelial Cell Interactions and Mitochondrial Dysfunction in Type 2 Diabetic Patients and Their Association With Silent Myocardial Ischemia
- (2013) A. Hernandez-Mijares et al. DIABETES CARE
- Sodium-Glucose Cotransporter Inhibition Prevents Oxidative Stress in the Kidney of Diabetic Rats
- (2012) Horacio Osorio et al. Oxidative Medicine and Cellular Longevity
- Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
- (2011) Muhammad A. Abdul-Ghani et al. ENDOCRINE REVIEWS
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
- (2009) R. A. DeFronzo DIABETES
- Intensive glucose control and macrovascular outcomes in type 2 diabetes
- (2009) F. M. Turnbull et al. DIABETOLOGIA
- Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes
- (2008) Peter Gæde et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started